

Supplemental Table 1. Demographic characteristics of propensity score-matched patients.

	No adjuvant therapy n=71 (%)	Adjuvant chemo with or without radiation n=71 (%)	Standardized Mean Differences	p-value
Age (years, median with IQR)	66(53-74)	60(54-68)		0.04
Age <50 years	15(21)	14(20)	0.03	1.00
Sex (female)	11(16)	12(17)	0.04	1.00
Race				1.00
White	70(99)	69(97)		
Black	0(0)	0(0)		
Other	1(1)	2(3)		
Year of diagnosis, median (IQR)	2008(2006-2010)	2008(2006-2009)		1.00
CDCC Score				0.92
0	50(70)	48(68)		
1	16(23)	18(25)	0.06	
2+	5(7)	5(7)	0.00	
Insurance status				0.17
Government	43(61)	33(47)		
Private	26(37)	37(52)		
None	2(3)	1(1)		
Facility type				0.87
Academic/research program	32(45)	34(48)	0.06	
Pathologic T stage				1.00
2	21(30)	20(28)		
3 or 4a	50(70)	51(72)	0.03	
Tumor size (mm, median with IQR)	33(23-45)	30(22-46)	0.01	0.64
Grade				1.00
Well/moderately differentiated	10(14)	11(16)	0.01	
Poorly differentiated	61(86)	60(84)		
Lymphovascular invasion	12(17)	11(16)	0.06	1.00
Adjuvant radiation	0(0)	47(66)		<0.001
Median survival (months) (IQR)	40(31-N/A)	48(35-72)		0.81
Mortality events	40(56)	46(65)		0.39
Median follow-up (months) (IQR)	33(15-68)	41(22-66)		0.36

IQR indicates Interquartile Range, CDCC, Charlson-Deyo Comorbidity Index

Supplemental Table 2. Number of NCCN 'high risk' factors in cohort, stratified by receipt of adjuvant chemotherapy with or without radiation.

High Risk Factors (number)	No adjuvant therapy	Adjuvant chemotherapy with or without radiation
1	276	70
2	36	20
3	1	0







